Schedule 13D ownership disclosure

Monopar Therapeutics Inc

Common Stock, $0.001 par value · CUSIP: 61023L207

Event date: 2024-12-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Monopar TherapeuticsReported CIK 0001645469

    Shares: 611,079.00 · Class: 11.6%

  • Hendricks DianeReported CIK 0001727478

    Shares: 704,829.00 · Class: 13.4%

  • Leo KarlReported CIK 0001727480

    Shares: 642,391.00 · Class: 13.4%

  • Pharma Investments LLCReported CIK 0001727496

    Shares: 611,079.00 · Class: 11.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001437749-25-003178
Form type
SCHEDULE 13D/A
Filer
Gem Pharmaceuticals LLC
CIK
CIK 1727356
Filed
Feb 07, 2025
Reporting period
Dec 09, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub